Reishi : le guide de référence

Résumé PubMed complet

Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that western blots portraying the protein p53 in Figs. 1C and 4C had previously appeared as p53 bands in an article published in 2010 in the journal PLoS One that featured the author Fei Wang in common, although the exprimental conditions were reported to be different in the previous paper. In addition, regarding the flow cytometric plots shown in Fig. 1D on p. 596, the 'HCT116 P53^' plots for the NTC (upper row) and 5‑FU (lower row) experiments appeared to show similar groupings of dots in specific areas of the quadrants, which would not have been anticipated if these experiments had been performed discretely under different experimental conditions, suggesting a fundamental flaw either in the way in which these experiments were performed or in how the results were outputted. Given that these issues have come to light, the Editor of Oncology Reports has decided that this paper should be retracted from the Journal on account of a lack of confidence in the presented data. After contacting the authors, they accepted the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 37: 594‑600, 2017; DOI: 10.3892/or.2016.5246].

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Jiang D, Wang L, Zhao T, Zhang Z, Zhang R, Jin J, Cai Y, Wang F
Revue : Oncology reports
Publication : 2026-08-21 · PMID 42627062 · DOI 10.3892/or.2026.9181

Résumé PubMed complet

Ganoderma lucidum is a medicinal mushroom widely recognized as a source of bioactive metabolites, particularly triterpenoids. Although most studies have focused on fruiting bodies and spores, the potential of cultured mycelial biomass as a source of functional secondary metabolites remains less explored. In this study, we isolated and characterized polycarpol from the mycelia of G. lucidum and evaluated its anti-melanogenic activity in B16F10 murine melanoma cells. Dried mycelia obtained after liquid culture were extracted with 70% ethanol, partitioned with ethyl acetate, and purified by repeated chromatographic separation. The isolated compound was identified as polycarpol by LC-ESI-MS, HR-MS/MS, and NMR spectroscopy, together with comparison with previously reported spectroscopic data. The anti-melanogenic activity of polycarpol was evaluated in α-MSH-stimulated B16F10 murine melanoma cells, a commonly used cellular model of melanogenesis. Polycarpol reduced α-melanocyte-stimulating hormone-induced cellular tyrosinase activity and melanin production at concentrations that did not markedly affect cell viability. Notably, 2 μg/mL (4.54 μM) polycarpol showed a melanin-inhibitory effect comparable to that of arbutin. Western blot analysis showed that polycarpol decreased the expression of microphthalmia-associated transcription factor, tyrosinase, and tyrosinase-related protein-1. In addition, polycarpol suppressed CREB phosphorylation and modulated the MAPK signaling pathways. These findings suggest that polycarpol inhibits melanogenesis through regulation of MITF-associated melanogenic signaling. Overall, this study demonstrates that cultured G. lucidum mycelia can produce anti-melanogenic triterpenoids and highlights cultured mycelial biomass as a controllable fungal material for exploring anti-melanogenic triterpenoids, although further optimization is required to improve production efficiency.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Park CH, Lee SC, Kang RW, Park YJ
Revue : Journal of fungi (Basel, Switzerland)
Publication : 2026-08-19 · PMID 42646151 · DOI 10.3390/jof12080625

Résumé PubMed complet

This work evaluated how ferulic acid (FA) impacted the conformational properties of whey protein isolate (WPI) and altered the environmental tolerance of oleogel/water (Og/W) emulsions formulated with Ganoderma lucidum spore oil (GLSO). Molecular dynamics simulation analyses revealed that FA interacted with α-lactalbumin via hydrogen bonding and hydrophobic interactions, whereas it bound into the hydrophobic cavity of β-lactoglobulin through a "lock-and-key" mode driven primarily by hydrophobic forces. Fourier transform infrared spectroscopy analysis verified that such non-covalent forces triggered the dissociation and structural extension of WPI, which was manifested as a significant loss of α-helix and β-sheet architectures along with a corresponding rise in random coils. FA addition increased the positive charge, mean droplet size, interfacial contact angle and antioxidant stability of WPI-FA nanoparticles when the WPI-to-FA ratio exceeded 1:2 (i.e., WPI was in excess relative to FA). The GLSO-based Og/W emulsions exhibited a weak gel structure with predominantly elastic characteristics. Furthermore, WPI-FA nanoparticles fabricated at a 2:1 ratio minimized emulsion droplet size and imparted optimal stability to the Og/W emulsions, demonstrating superior freeze-thaw and salt resistance, alongside suppressed GLSO flavor release. This work provides critical insights into tailoring protein-polyphenol interactions to stabilize GLSO-based Og/W emulsion delivery systems for food applications.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude de recherche à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

La portée de cette publication dépend du modèle, de la préparation, de la dose et des critères étudiés. Le résumé PubMed permet d’en vérifier le contexte exact.

Source

Auteurs : Yan W, Bao Y, Wang H, Xu S, He C, Wang Z, Jiang J
Revue : Gels (Basel, Switzerland)
Publication : 2026-08-17 · PMID 42644978 · DOI 10.3390/gels12080735

Résumé PubMed complet

Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with unsatisfactory prognosis and ongoing therapeutic challenges. Ganoderma lucidum has been widely investigated for anticancer activity, but the specific monomeric ganoderic acids that may contribute to anti-ESCC effects and their potential target context remain insufficiently characterized. Compounds and targets were prioritized through network pharmacology, ADME evaluation, disease-target integration and TCGA-based clinical bioinformatics. Molecular docking and 100-ns molecular dynamics (MD) simulations were used to evaluate putative ligand-target binding stability. The effects of ganoderic acid A (GA-A) and ganoderic acid D (GA-D) were assessed in ESCC and normal esophageal epithelial cells using image-based cell counting, EdU incorporation assays, flow cytometric cell-cycle and apoptosis analyses, and immunoblotting of mTORC1-associated readouts. Nine compounds and 191 drug-disease intersection targets were identified. GA-A and GA-D were prioritized as core ganoderic acid monomers based on network connectivity, pharmacological relevance and experimental feasibility. Enrichment analysis implicated cancer-related signaling, including PI3K-Akt/mTOR-associated pathways. Docking and MD simulations supported stable putative interactions between GA-A/GA-D and mTOR. In vitro, both compounds reduced cell number and EdU incorporation in ECSS cells, and induced G0/G1 accumulation and apoptosis, with GA-D showing stronger anti-proliferative activity than GA-A under the tested conditions. HEEC cells were less sensitive under the tested conditions. GA-A and GA-D also reduced phosphorylated S6 and 4EBP1 levels. This study identifies GA-A and GA-D, particularly GA-D, as candidate anti-proliferative monomers from G. lucidum against ESCC. The findings provide a focused, experimentally supported basis for further mechanistic evaluation of ganoderic acids, including target engagement assays and drug-treated transcriptomic profiling.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Wang Y, Xie Y, Meng S, Huang J, Hu H, Wu M, Chen Q, Wu P, et al.
Revue : Biochemical and biophysical research communications
Publication : 2026-08-14 · PMID 42628332 · DOI 10.1016/j.bbrc.2026.154445

Résumé PubMed complet

Medicinal plants are widely used in traditional medicine to treat various diseases, especially in communities with limited access to conventional healthcare. Ganoderma lucidum (Reishi mushroom) is a medicinal fungus that has been widely used in traditional medicine systems, particularly in East Asia, for the prevention and treatment of inflammatory disorders, gastrointestinal ailments, and general health promotion due to its rich content of bioactive compounds, with antioxidant and anti-inflammatory properties. Its long-standing ethnomedicinal use as a tonic and therapeutic agent supports its relevance as a natural source of bioactive compounds with potential pharmacological benefits. This study aimed to investigate the phytochemical composition, pharmacological activities, toxicity profile, and in silico therapeutic potential of the methanolic extract of the fruiting body of G. lucidum (GLFME) with a particular focus on its antioxidant and anti-inflammatory effects. An integrated in vitro assay, in vivo models, and molecular docking analyses were employed to evaluate the pharmacological potential of GLFME. The samples were air-dried, ground into a fine powder, and extracted in methanol (1:20, w/v) for 10 days, followed by a filtration-evaporation cycle under low pressure to produce a crude methanol extract. A fraction of the extract was subjected to phytochemical profiling through UV densitometry, FTIR, and GC/MS analysis. Antioxidant activity was evaluated using DPPH and ferric reducing antioxidant power (FRAP) assays. Cytotoxicity and thrombolytic activity were assessed using brine shrimp lethality and clot lysis assays. Analgesic, anti-inflammatory, and antidiarrheal activities were evaluated in vivo using animal models. Acute toxicity studies were conducted to assess safety. Molecular docking was performed to determine the binding affinity of identified compounds toward human catalase (PDB ID: 1DGH), a key antioxidant enzyme belonging to the oxidoreductase class that plays a central role in cellular redox homeostasis. GLFME contained high levels of phenolics (215.63 ± 17 mg GAE g-1) and flavonoids (467.34 ± 35 QAE g-1). The extract showed strong antioxidant activity with a DPPH IC50 value of 0.969 ± 0.008 μg mL-1. Significant thrombolytic activity (p < 0.01) and mild cytotoxicity (LC50 = 13.15 ± 1.2 μg mL-1) were observed. Acute toxicity studies indicated an LD50 > 1600 mg kg-1. In vivo studies demonstrated significant analgesic, anti-inflammatory, and antidiarrheal effects. Docking results revealed strong binding affinities of GC-MS-identified compounds toward human catalase (PDB ID: 1DGH). These findings suggest that GLFME possesses significant antioxidant and anti-inflammatory pharmacological potential and may serve as a promising natural source for future nutraceutical and therapeutic development.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique in vitro à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude est menée sur des cellules ou en laboratoire. Elle décrit un signal biologique, pas un bénéfice démontré chez l’humain.

Source

Auteurs : Akhter Nifa MS, Abdullah M, Islam M, Khatun S, Bhuiyan AA, Shanta MA, Islam MA, Sheikh MR, et al.
Revue : Journal of ethnopharmacology
Publication : 2026-08-13 · PMID 42595068 · DOI 10.1016/j.jep.2026.122298

Résumé PubMed complet

Depression is a common and serious comorbidity in patients with cancer and is associated with worse clinical outcomes and reduced quality of life. Gut microbiota dysbiosis has been implicated as a pathogenic factor, potentially driving depressive symptoms through metabolic alterations and disruption of the gut-brain axis-mechanisms that may also contribute to cancer progression. The medicinal mushroom Ganoderma lucidum has been investigated primarily for its immunomodulatory effects in patients with cancer, and emerging preclinical evidence suggests that it may possess antidepressant properties, positioning it as a candidate for microbiota-targeted intervention. Preclinical evidence indicates that G. lucidum can act as a gut microbiota modulator and alleviate depressive-like behaviors in animal models, with mechanisms involving the correction of dysbiosis and the normalization of key metabolic pathways, including those related to short-chain fatty acids and tryptophan, thereby improving inflammatory tone and neuroendocrine function. In contrast, human studies have largely focused on its immunomodulatory and quality-of-life effects in patients with cancer, with limited direct assessment of depression-related outcomes. Consequently, current mechanistic insights are derived predominantly from animal studies and require validation in large-scale human trials. This review proposes that gut microbiota modulation represents a plausible and potentially important mechanism through which G. lucidum may exert antidepressant effects in the context of cancer comorbidity, namely that the "G. lucidum-gut microbiota-depression" pathway is an inferred translational framework rather than an established clinical mechanism. Nonetheless, this framework provides a rationale for future efforts to develop G. lucidum and its active components into microbiota-based therapeutics for cancer-related depression.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme revue de littérature à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Pas directement. Il s’agit d’une synthèse de travaux qui peuvent inclure des données humaines et précliniques. Il faut vérifier les études incluses avant de tirer une conclusion clinique.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette revue rassemble des travaux qui peuvent utiliser des modèles, des doses et des préparations différents. Elle ne remplace pas un essai clinique sur un produit précis.

Source

Auteurs : Du XY, Bu F, Ling ZQ
Revue : The Journal of nutrition
Publication : 2026-07-17 · PMID 42468722 · DOI 10.1016/j.tjnut.2026.101731

Résumé PubMed complet

Ganoderma lucidum fermentation (GLF) serves as a sustainable biotransformation platform that precisely modulates the chemical profiles and bioactivities of natural products through enzymatic hydrolysis, microbial metabolic remodeling, and substrate-microbe crosstalk. This review systematically elucidates the GLF-driven structural modifications of key compounds- including polysaccharides, saponins, triterpenoids, flavonoids, and proteins. These structural optimizations synergistically enhance multiple bioactivities: the increased content of deglycosylated ginsenosides enhances antitumor activity, while the antioxidant and prebiotic effects of polysaccharides are potentiated through the regulation of gut microbiota and short-chain fatty acid (SCFA) production. The core mechanisms involve a sophisticated interplay of specific enzyme catalysis, fungal endogenous biosynthesis, and a dynamic "substrate degradation-product synthesis" metabolic cycle. Finally, we emphasize that integrating multi-omics and synthetic biology is crucial for achieving precision control of GLF and advancing its translation in functional foods and drug discovery.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme revue de littérature à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Pas directement. Il s’agit d’une synthèse de travaux qui peuvent inclure des données humaines et précliniques. Il faut vérifier les études incluses avant de tirer une conclusion clinique.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette revue rassemble des travaux qui peuvent utiliser des modèles, des doses et des préparations différents. Elle ne remplace pas un essai clinique sur un produit précis.

Source

Auteurs : Liu Y, Liu B, Zhu T, Chen N, Chu J, Wei H, Li W
Revue : Current topics in medicinal chemistry
Publication : 2026-07-14 · PMID 42483913 · DOI 10.2174/0115680266461232260515094327

Résumé PubMed complet

Obesity is a global health crisis and a critical risk factor for male infertility, impairing testicular structure and function through hormonal imbalance and oxidative stress. Current therapeutic strategies are often unsatisfactory due to limited efficacy or adverse effects. This study investigated the protective effects and potential molecular mechanisms of Ganoderma lucidum (GL) polysaccharides and triterpenoids against testicular injury in high-fat diet-induced obese male rats. After 12-week GL intervention, reproductive function in obese male rats showed improvement: GL increased litter size, improved sperm motility, reduced sperm DNA fragmentation, and restored serum testosterone, inhibin B, and leptin levels. It also alleviated testicular histopathological damage, downregulated PPT1, and maintained vimentin expression. Notably, GL facilitated delayed fertility recovery and showed a trend toward improved cumulative reproductive success, although fixed-time pregnancy rates were not significantly changed. Mechanistically, GL is associated with enhanced Nrf2 pathway activity, increased SOD1, HO-1, NQO1, and GPX4 levels, and decreased MDA and ROS accumulation, thereby attenuating oxidative stress. It preserved mitochondrial integrity, suppressed germ cell apoptosis (downregulating Bax and caspase-3, upregulating Bcl-2), and promoted cell proliferation. These findings indicate that GL polysaccharides and triterpenoids effectively ameliorate obesity-induced testicular dysfunction, and these beneficial effects are associated with Nrf2-mediated antioxidant responses, mitochondrial homeostasis, apoptosis regulation, and hormonal balance. GL may serve as a promising candidate for obesity-related male infertility.

Résumé dans la langue de publication · Anglais

Questions et réponses

Quel type d’étude est-ce ?

Cette publication est classée comme étude préclinique animale à partir de son indexation et de son résumé PubMed.

L’étude apporte-t-elle des données chez l’humain ?

Non. Le résumé PubMed ne décrit pas un essai mené chez l’humain. Les résultats restent précliniques.

Cette publication teste-t-elle un produit SporeLife ?

Non. Elle porte sur Reishi ou sur l’un de ses composés ou préparations. La formulation, la dose et les contrôles peuvent différer de ceux d’un produit SporeLife.

Que peut-on en conclure ?

Cette étude porte sur un modèle animal. Elle aide à explorer un mécanisme, mais ne permet pas de conclure à un effet chez l’humain.

Source

Auteurs : Yanhong L, Wei L, Yunlin H, Yanfeng X, Wenjie Z, Siyuan W, Chuan Q
Revue : Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Publication : 2026-07-13 · PMID 42442304 · DOI 10.1016/j.biopha.2026.119765